Article first published online: 4 OCT 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 4, pages 1252–1260, October 2012
How to Cite
Rice, J. P., Burnett, D., Tsotsis, H., Lindstrom, M. J., Cornett, D. D., Voermans, P., Sawyer, J., Striker, R. and Lucey, M. R. (2012), Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology, 56: 1252–1260. doi: 10.1002/hep.25770
Potential conflict of interest: Dr. Lucey is or has been site principal investigator in clinical trials of antiviral treatment for hepatitis C virus infection sponsored by the following pharmaceutical companies: Hyperion; Human Genome Sciences; Bristol-Myers Squibb; Gilead; Vertex; Abbott; Salix; and Novartis. He received grants from Abbot, Gilead, Salix, Hyperion, Bristol Myers Squibb, Novartis, HGS, and Vertex.
The funders had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript for this article.
- Issue published online: 4 OCT 2012
- Article first published online: 4 OCT 2012
- Accepted manuscript online: 13 APR 2012 12:43PM EST
- Manuscript Accepted: 2 APR 2012
- Manuscript Received: 11 SEP 2011
- American Cancer Society Research Scholar. Grant Number: 07-077-01; to R.S.
- University of Wisconsin Institute for Clinical and Translational Research
- National Institutes of Health (NIH) Clinical and Translational Science Award. Grant Number: 1UL1RR025011
- Clinical and Translational Science Award program of the National Center for Research Resources, NIH. Grant Number: 1UL1RR025011
The prevalence of chronic hepatitis C virus (HCV) infection among incarcerated individuals in the United States is estimated to be between 12% and 31%. HCV treatment during incarceration is an attractive option because of improved access to health care and directly observed therapy. We compared incarcerated and nonincarcerated HCV-infected patients evaluated for treatment at a single academic center between January 1, 2002 and December 31, 2007. During this period, 521 nonincarcerated and 388 incarcerated patients were evaluated for HCV treatment. Three hundred and nineteen (61.2%) nonincarcerated patients and 234 (60.3%) incarcerated patients underwent treatment with pegylated interferon and ribavirin. Incarcerated patients were more likely to be male, African-American race, and have a history of alcohol or intravenous drug use. Treated incarcerated patients were less likely to have genotype 1 virus and were less likely to have undergone previous treatment. There was a similar prevalence of coinfection with human immunodeficiency virus (HIV) in both groups. A sustained viral response (SVR) was achieved in 97 (42.9%) incarcerated patients, compared to 115 (38.0%) nonincarcerated patients (P = 0.304). Both groups had a similar proportion of patients that completed a full treatment course. Stepwise logistic regression was conducted, and the final model included full treatment course, non-genotype 1 virus, younger age at treatment start, and negative HIV status. Incarceration status was not a significant predictor when added to this model (P = 0.075). Conclusion: In a cohort of HCV-infected patients managed in an academic medical center ambulatory clinic, incarcerated patients were as likely to be treated for HCV and as likely to achieve an SVR as nonincarcerated patients. (HEPATOLOGY 2012)